: clinicaltrials_resource:0000118aa46e7c26af559737dc5be2b4http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The HAM-D measures the severit ...... ek 8 minus the Baseline value. | |
: clinicaltrials_resource:000026652b72c8457ecae4232ef7819bhttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | OR is defined as the number of ...... L. nPR: persistent nodules BM. | |
: clinicaltrials_resource:000036d07b2489619e85b7dcd5e0f736http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression. | |
: clinicaltrials_resource:00003aa5b9e3db40e06a7d66e7826d47http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | 3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos | |
: clinicaltrials_resource:00003dcf43e1c3f68115efa8e9ce1941http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | gait characteristics, smoothne ...... cost, SAFFE, GES, figure of 8 | |
: clinicaltrials_resource:000057dd7c420208c0b09c4fdc3fcf19http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Concentrations were expressed ...... 7F, 9V, 14, 18C, 19F, and 23F. | |
: clinicaltrials_resource:00005ec47c408d18cf469b6bfc96c212http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The TTLUS is defined as the nu ...... ial to the time of withdrawal. | |
: clinicaltrials_resource:000064868dd7d872c050c90eb2d4ab96http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Percentage of patients who's d ...... ath in absence of progression. | |
: clinicaltrials_resource:0000877790ab42df9b393fc0772dd1b4http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Thiazidic diuretic | |
: clinicaltrials_resource:0000b6f1b6b4d159c16e3abcf84587cfhttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The proportion of subjects in ...... oup compared to placebo group. | |
: clinicaltrials_resource:0000d6976b16ff864d4a4a05aa483f45http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously. | |
: clinicaltrials_resource:0000e5bcaaa80cc7b1f88125dca72c9ahttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | To determine the mean change i ...... ocular reading) from baseline. | |
: clinicaltrials_resource:0000f452bd285a79e2c3a23736438a7ehttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Incidence of serious adverse device effects | |
: clinicaltrials_resource:00012b2d39130f79c2cd4d635e5f9c83http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Graded according to NCI CTC version 2.0. | |
: clinicaltrials_resource:00015fccf791496c3befcec527b3f33fhttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Change from Baseline in Genera ...... el of general procrastination. | |
: clinicaltrials_resource:00017127769a01788cb961825ac463c5http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | -pressure pain threshold (PPT) ...... ured with a digital algometer. | |
: clinicaltrials_resource:00017f8d5063d7e79f785ddd4b650ddchttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | This is defined as any symptom ...... , or back pain; and/or chills. | |
: clinicaltrials_resource:0001d54261ea562ae7b516fb226d890fhttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The primary outcome will be th ...... ent as usual (TAU) conditions. | |
: clinicaltrials_resource:0001de32034820ee2f457238f07c96f9http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Defined as the time spent walk ...... reaking for more than a minute | |
: clinicaltrials_resource:0001e036a0dc1f1e401f37244472d6e9http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Prednihexal (Prednisolon), dai ...... . Finally 5 mg for four weeks. | |
: clinicaltrials_resource:0001e86db058b3336d3c23d482276263http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The arm is as a control group ...... ized TNFα monoclonal antibody. | |
: clinicaltrials_resource:0001f63a35e2c5d2c2169e7b5753252chttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Objective response is defined ...... s the time after radiotherapy. | |
: clinicaltrials_resource:00020ce88d3df818edd2182756f149b6http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Our primary hypothesis will te ...... control group after 12 months. | |
: clinicaltrials_resource:00020f86e9dacaae71bd9224c590bdd2http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Dual X-ray Absorptiometry (DXA) | |
: clinicaltrials_resource:00021e80640d139223721e889a199de5http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy | |
: clinicaltrials_resource:00022ae05f46afb06cd2862e4f91e6f9http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | NIH Clinical Center Detailed Web Page | |
: clinicaltrials_resource:000233d94ca19eec7dc5c18305087ff6http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Change in clinic, home, centra ...... tiffness (pulse wave velocity) | |
: clinicaltrials_resource:00024c8e82b3fd5417d62dc385d6ffa7http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Proportion of subjects in mCRE ...... is absent with repeat culture) | |
: clinicaltrials_resource:0002564904e6e9a71837310686cbf2achttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Patients receive docetaxel IV ...... hen every 6 months thereafter. | |
: clinicaltrials_resource:000256a34aa461a70155e6c3b0a9414ahttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Decitabine 15 mg/m2 i.v. - single arm | |
: clinicaltrials_resource:000282e5d9ed8c4b0c9f37c63b9c8cd8http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Area under the Concentration v ...... like peptide-1 in blood plasma | |
: clinicaltrials_resource:00029673dccfdf9bb84f9090ca7fa694http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | I.e. Comparison of GLP-1 secre ...... ly b) healthy volunteers only. | |
: clinicaltrials_resource:000298a379795b2677064327fb086835http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Bioavailability is defined as ...... n to intravenous (IV) infusion | |
: clinicaltrials_resource:00029d72888c68f98afeb15db20e6a7dhttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | 24 hour urine creatinine clear ...... occurs on Study Days 0 and 1. | |
: clinicaltrials_resource:0002a13cc6dd54288c9ba54c89498d70http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Acute success is defined as confirmation of entrance block in all pulmonary veins | |
: clinicaltrials_resource:0002a161db0cdb8edb446dc9d98797e0http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | assess the safety of increased ...... ts in first complete remission | |
: clinicaltrials_resource:0002f17f747d4ccbf727b56e0b5c5979http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Diabetic patients will complet ...... ous Insulin treatment sessions | |
: clinicaltrials_resource:000315c8e833632bd80a586f6b13bad4http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Single-dose cohorts | |
: clinicaltrials_resource:000344ada83e0edda440d131e9c340c1http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The primary objective of this ...... lts <50 copies/mL is reported. | |
: clinicaltrials_resource:00035ccdd872b4fdc13489a7f858bf92http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Patients receive bortezomib IV ...... sion or unacceptable toxicity. | |
: clinicaltrials_resource:00036588154d544ef353f74477e61e12http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The primary efficacy endpoint ...... ic core laboratory assessment. | |
: clinicaltrials_resource:0003683e666584ceb49f49d793781b45http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | 5 mg of GSK256073 | |
: clinicaltrials_resource:000382eadc1d621b7320becd458b706dhttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | The difference between the Pre ...... ive whole body protein balance | |
: clinicaltrials_resource:0003b2ee2fcf9db3011ff4d8ceb7d49ehttp://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Using a 10-cm unscaled visual analog scale; 0 = no pain, 10 = very painful | |
: clinicaltrials_resource:0003de98eaf909c4bf6c7c014d5b0f32http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | One group will receive the stu ...... One group will receive placebo | |
: clinicaltrials_resource:0003deaa16de6c54334c6dc5b1357690http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | PANSS rates severity of psycho ...... icating more severe pathology. | |
: clinicaltrials_resource:0003e4ca80f29cc523e83d76e86de649http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | low fat diet for two weeks. | |
: clinicaltrials_resource:0003fbe95b4e7760790e9706ebe45883http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Measured as the amount of pain medication and equianalgesic equivalents to morphine. | |
: clinicaltrials_resource:00041c4bcc8b2dd36a1d6146fed10345http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Proportion of patients with a positive pregnancy test | |
: clinicaltrials_resource:000446ac57cd57683bb56638b0905ba0http://bio2rdf.org/ Create a prefix for http://bio2rdf.org/ Hit Enter to save Double click to create a prefix | dct:description | Patients admitted with advance ...... e approach them for the study. |